{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:43:03Z","timestamp":1761986583267,"version":"build-2065373602"},"reference-count":37,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Hypersensitivity reactions (HSR) to tumor necrosis factor \u03b1 inhibitors (TNFi) can occur but data about skin testing in such reactions are limited.\n                    <jats:bold>Objective:<\/jats:bold>\n                    To evaluate skin testing in patients with HSRs to TNFi.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A detailed review of demographics and clinical characteristics, features of index reactions, results of skin tests, and outcomes of desensitization protocols were obtained.\n                    <jats:bold>Results:<\/jats:bold>\n                    The cohort comprised 64 patients (women\/men: 41\/23). Treatment distribution included\n etanercept (n = 50 [78.1%]), adalimumab (n = 11 [17.2%]), and infliximab (n = 3 [4.7%]). HSRs were seen as an injection-site reaction (ISR) in 47 patients (73.4%), generalized urticaria in 8 patients (12.5%), and anaphylaxis in 3 patients (4.7%). Forty-four patients (44\/64 [72%]) had positivity\n on skin tests as either skin-prick test (SPT) or intradermal test (IDT). Among other reaction types, the patients with ISRs exhibited the highest skin test positivity (p\u2009=\u20090.043). Among the 17 patients who underwent rapid subcutaneous or intravenous desensitization, 15 patients\n (88.2%) had positive skin test results, and all desensitization procedures were successfully completed, despite some experiencing local breakthrough reactions (BTR).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study, which includes the largest number of patients reported in the literature, highlights\n the important role of skin testing in diagnosing HSRs to TNFi. Notably, etanercept demonstrated the highest positivity rate. Successful completion of desensitization protocols despite some BTRs highlights the importance of desensitization in patients experiencing HSRs to these treatments.\n                  <\/jats:p>","DOI":"10.2500\/aap.2025.46.250079","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T04:32:17Z","timestamp":1761712337000},"page":"489-497","source":"Crossref","is-referenced-by-count":1,"title":["The value of skin testing with tumor necrosis factor-inhibitors in patients with local and systemic hypersensitivity reactions"],"prefix":"10.2500","volume":"46","author":[{"given":"Nilay","family":"Orak Akbay","sequence":"first","affiliation":[{"name":"From the Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betul","family":"Ozdel Ozturk","sequence":"additional","affiliation":[{"name":"From the Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Doganci","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Atat\u00fcrk Sanatorium Training and Research Hospital, Ankara, Turkey; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Celebi Sozener","sequence":"additional","affiliation":[{"name":"From the Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebnem","family":"Ataman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Physical Medicine and Rehabilitation, School of Medicine, Ankara University, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevim","family":"Bavbek","sequence":"additional","affiliation":[{"name":"From the Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J Clin Med"},{"key":"B2","first-page":"40","article-title":"The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis","volume":"25","author":"Dore","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current knowledge and management of hypersensitivity reactions to monoclonal antibodies","volume":"5","author":"Picard","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","article-title":"Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis","volume":"173","author":"Maneiro","year":"2013","journal-title":"JAMA Intern Med"},{"key":"B6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1398-9995.2007.01536.x","article-title":"Injection site reactions to TNF-alpha blocking agents with positive skin tests","volume":"63","author":"Benucci","year":"2008","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.aller.2012.04.006","article-title":"Injection site reaction to adalimumab: positive skin test and successful rapid desensitisation","volume":"41","author":"Bavbek","year":"2013","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1398-9995.2011.02601.x","article-title":"Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization","volume":"66","author":"Bavbek","year":"2011","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.anai.2011.11.004","article-title":"Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab","volume":"108","author":"Puxeddu","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","first-page":"1","article-title":"TNF-Alfa Inhibit\u00f6rleri Ile Tedavi Seyrinde Geli\u015fen Alerjik Reaksiyonlar","author":"Bavbek","year":"2019"},{"key":"B11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archderm.142.2.218","article-title":"Eosinophilic cellulitislike reaction to subcutaneous etanercept injection","volume":"142","author":"Winfield","year":"2006","journal-title":"Arch Dermatol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mcna.2019.09.003","article-title":"Drug hypersensitivity reactions","volume":"104","author":"Dykewicz","year":"2020","journal-title":"Med Clin North Am"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archderm.144.9.1190","article-title":"Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab","volume":"144","author":"Paltiel","year":"2008","journal-title":"Arch Dermatol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","article-title":"Hypersensitivity to biological agents-updated diagnosis, management, and treatment","volume":"3","author":"Galvao","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.15586\/aei.v51i5.946","article-title":"Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in adults: beyond current classification","volume":"51","author":"\u00c7er\u00e7i","year":"2023","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.jaip.2020.10.055","article-title":"Effect of drug desensitization on drug hypersensitivity-related quality of life","volume":"9","author":"Kepil \u00d6zdemir","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"crossref","first-page":"100619","DOI":"10.1016\/j.waojou.2021.100619","article-title":"Rapid drug desensitization with platin-based chemotherapy: analysis of risk factors for breakthrough reactions","volume":"15","author":"Gorgulu Akin","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000496745","article-title":"Rapid drug desensitization with chemotherapeutics (platins, taxanes, and others): a single-center retrospective study","volume":"179","author":"Kendirlinan","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000454808","article-title":"Rapid drug desensitization with biologics: a single-center experience with four biologics","volume":"171","author":"Bavbek","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.55730\/1300-0144.5914","article-title":"The relationship between drug-induced immunogenicity and hypersensitivity reactions and skin tests related to infliximab, etanercept and adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"54","author":"Doganci","year":"2024","journal-title":"Turk J Med Sci"},{"key":"B22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.iac.2017.06.001","article-title":"Subcutaneous injectable drugs hypersensitivity and desensitization: insulin and monoclonal antibodies","volume":"37","author":"Bavbek","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"B23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jaip.2015.01.009","article-title":"Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients","volume":"3","author":"Bavbek","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.iac.2009.04.012","article-title":"Rapid desensitization for hypersensitivity reactions to medications","volume":"29","author":"Castells","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"key":"B25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3892\/etm.2021.10381","article-title":"Hypersensitivity reactions to monoclonal antibodies: classification and treatment approach (review)","volume":"22","author":"Pintea","year":"2021","journal-title":"Exp Ther Med"},{"key":"B26","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3899\/jrheum.120791","article-title":"Etanercept allergy and anaphylaxis","volume":"39","author":"Quismorio","year":"2012","journal-title":"J Rheumatol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/all.14984","article-title":"Hypersensitivity reactions to biologicals: an EAACI position paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/ijms18061316","article-title":"Drug hypersensitivity and desensitizations: mechanisms and new approaches","volume":"18","author":"de Las Vecillas S\u00e1nchez","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B29","first-page":"893","article-title":"Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein","volume":"137","author":"Zeltser","year":"2001","journal-title":"Arch Dermatol"},{"year":"2008","key":"B30"},{"key":"B31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/cea.12098","article-title":"Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab","volume":"43","author":"Matucci","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"B32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy"},{"key":"B33","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/all.12620","article-title":"Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization","volume":"70","author":"Alvarez-Cuesta","year":"2015","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","article-title":"A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents","volume":"7","author":"Madrigal-Burgaleta","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.alit.2016.09.002","article-title":"Rapid subcutaneous desensitization for treatment of hypersensitivity reactions to etanercept in two patients with positive basophil activation test","volume":"66","author":"de la Varga Mart\u00ednez","year":"2017","journal-title":"Allergol Int"},{"key":"B36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/eci.11.75","article-title":"Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies","volume":"8","author":"Hong","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4274\/atfm.galenos.2021.92005","article-title":"A patient with local hypersensitivity reactions to three TNF-\u03b1 inhibitors and local\/systemic hypersensitivity reactions to tocilizumab: desensitization to tocilizumab.","volume":"75","author":"Ozturk","year":"2022","journal-title":"Ankara \u00dcniversitesi T\u0131p Fak\u00fcltesi Mecmuas\u0131"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000006\/art00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:22:35Z","timestamp":1761974555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,1]]}},"alternative-id":["1088-5412(20251101)46:6L.489;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250079","relation":{},"ISSN":["1088-5412"],"issn-type":[{"type":"print","value":"1088-5412"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}